Triple

T19773765
Position Surface form Disambiguated ID Type / Status
Subject respiratory syncytial virus E474952 entity
Predicate hasProphylaxis P137290 FINISHED
Object nirsevimab
Nirsevimab is a long-acting monoclonal antibody used to prevent severe respiratory syncytial virus (RSV) infection in infants and young children.
 E1394342 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: nirsevimab | Statement: [respiratory syncytial virus, hasProphylaxis, nirsevimab]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: nirsevimab
Context triple: [respiratory syncytial virus, hasProphylaxis, nirsevimab]
  • A. ansuvimab
    Ansuvimab is a monoclonal antibody used as a therapeutic treatment for infection caused by Zaire ebolavirus (Ebola virus).
  • B. odesivimab
    Odesivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
  • C. Comirnaty
    Comirnaty is the brand name of the Pfizer–BioNTech mRNA COVID-19 vaccine used worldwide for the prevention of coronavirus infection.
  • D. Vaxzevria COVID-19 vaccine
    Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
  • E. Hemlibra
    Hemlibra is a monoclonal antibody medication used to prevent or reduce bleeding episodes in people with hemophilia A, including those with factor VIII inhibitors.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: nirsevimab
Triple: [respiratory syncytial virus, hasProphylaxis, nirsevimab]
Generated description
Nirsevimab is a long-acting monoclonal antibody used to prevent severe respiratory syncytial virus (RSV) infection in infants and young children.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: nirsevimab
Target entity description: Nirsevimab is a long-acting monoclonal antibody used to prevent severe respiratory syncytial virus (RSV) infection in infants and young children.
  • A. ansuvimab
    Ansuvimab is a monoclonal antibody used as a therapeutic treatment for infection caused by Zaire ebolavirus (Ebola virus).
  • B. odesivimab
    Odesivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
  • C. Comirnaty
    Comirnaty is the brand name of the Pfizer–BioNTech mRNA COVID-19 vaccine used worldwide for the prevention of coronavirus infection.
  • D. Vaxzevria COVID-19 vaccine
    Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
  • E. Hemlibra
    Hemlibra is a monoclonal antibody medication used to prevent or reduce bleeding episodes in people with hemophilia A, including those with factor VIII inhibitors.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d8e51a43a08190956bc6df13c91a77 completed April 10, 2026, 11:55 a.m.
NER Named-entity recognition batch_69e6535e450c8190a2628245ae0d0bd3 completed April 20, 2026, 4:25 p.m.
NED1 Entity disambiguation (via context triple) batch_6a07bd76afe08190b958bd49acf21c4a completed May 16, 2026, 12:42 a.m.
NEDg Description generation batch_6a07be5426c48190bb7b0fc315fa2f6a completed May 16, 2026, 12:46 a.m.
NED2 Entity disambiguation (via description) batch_6a07bf9682fc8190a33ea75dba8d88d6 completed May 16, 2026, 12:51 a.m.
Created at: April 10, 2026, 1:48 p.m.